IL2RA and chronic myelogenous leukemia, BCR-ABL1 positive: Using a large number of CP-CML (n = 22) progressing toward BC-CML (n = 14) and AML cases, we have shown that the expression of CD25 is increased during the progression of CML, and that this could be a potential therapeutic target (Figure 8A,B).